Creative Biolabs Blog

Menu

Skip to content
  • Drug Discovery Research
  • Immunotherapy Research
  • Antibody Engineering Research

Industry Leader

With extensive experience, Creative Biolabs aims to offer you the best in the field of antibody

De Novo Antibody Sequencing

Antibody Sequencing Service Supports Your Antibody Engineering with All-around Service System.

Global Market

Creative Biolabs serves customers from the USA, Canada, European countries and more

Single Domain Antibody

Single domain antibody—the most promising antibody in disease diagnosis, genetic modification and more

02Jan/18

Prediction of the World’s Top 10 Best-selling Drugs in 2018

January 2, 2018Drug Discovery Research, NewsDrug information, Therapeutic Antibodybiolabs

Evaluate Pharma, a well-known market research organization in the field of medicine, recently released the report “EP Vantage 2018 Preview”, in which it reviewed the new drug approval in 2017, and predictedRead More…

21Dec/17
CAR-T

Latest Research Results on CAR-T Therapy Reveal a Possible Reason of CAR-T Neurotoxicity

December 21, 2017Immunotherapy ResearchCAR-Tbiolabs

There is no doubt that this year marks the beginning of CAR-T therapy owing to the advent of two CAR-T therapies and the changes that these therapies have brought to the lives ofRead More…

05Dec/17

What Is the ROI of Anti-cancer Drug R&D? The Latest Research Showed that an Investment of $ 648 Million Can Generate Revenue of $ 1,658 Million

December 5, 2017Drug Discovery Research, NewsAntibody Discovery, Therapeutic Antibodybiolabs

  A new study recently calculated the development costs of 10 new anti-tumor drugs over the 10-year period between 2006 and 2015, and found that the median development time for these 10Read More…

22Nov/17
Brentuximab Vedotin

Collaboration to Evaluate Combination of Nivolumab + Brentuximab Vedotin in Phase III Trial in Relapsed Hodgkin Lymphoma Expanded

November 22, 2017Antibody Engineering Research, NewsADC, Antibody Drug Conjugationbiolabs

“Brentuximab Vedotin (Antibody-drug conjugate, ADC)was approved by the FDA in 2011 as the first new therapeutic option for patients with Hodgkin lymphoma in more than 30 years. Currently, brentuximab vedotin and nivolumabRead More…

21Nov/17

FDA Taking New Steps to Better Inform Physicians about Biosimilars Through Education about these Potentially Cost-Saving Options

November 21, 2017Antibody Engineering Researchbiosimiar, Therapeutic Antibodybiolabs

“The global biosimilar market is growing rapidly as patents on blockbuster biologic drugs expire.Although many companies are keen on getting a share in the biosimilars market given its promising outlook, bringing theseRead More…

Leave a comment
06Nov/17

Actemra/RoActemra® Is Approved by FDA for the Treatment of Cytokine Release Syndrome Caused by CAR-T Therapy

November 6, 2017Immunotherapy ResearchActemra/RoActemra®, CAR-T, CAR-T cell therapy, cytokine release syndromebiolabs

Actemra/RoActemra® is the first FDA approved drug for treatment of serious or fatal cytokine release syndrome (CRS) caused by CAR-T therapy; CAR-T cell therapy is an immunotherapy used to treat certain typesRead More…

31Oct/17

Top 10 R&D Expense of Pharmaceutical Giants (II)

October 31, 2017Antibody Engineering Researchantibody development, Antibody Discovery, biosimiar, Therapeutic Antibodybiolabs

6. AstraZeneca   AstraZeneca’s research and development line was mixed last year. The Clinical Phase III trial result of Olaparib used for the treatment of BRCA mutations related advanced ovarian cancer afterRead More…

Leave a comment
30Oct/17

Chinese Scientists Discovered Strong Oncolytic Virus Synergist

October 30, 2017Immunotherapy Research, NewsCAR-T, ERAD pathway, M1, oncolytic virusbiolabs

On August 24th, a reporter was informed from Prof. Guangmei Yan research group at Zhongshan University that this group of researchers identified and gained oncolytic virus M1 synergist with accurate treatment ofRead More…

28Sep/17
Income and R&D expense proportion of pharmaceutical giants in 2016

Top 10 R&D Expense of Pharmaceutical Giants (i)

September 28, 2017Antibody Engineering Research, Newsantibody development, Antibody Discovery, biosimiar, Therapeutic Antibodybiolabs

Generally, when the business of a pharmaceutical giant reaches a plateau, its business volume won’t change much during this period. Instead, it will try to optimize its structure, including R&D and productionRead More…

11Sep/17
An autoimmune disease is a pathological condition resulting from an abnormal immune response to tissues that can exist in the body,

Car-T for Autoimmune Disease and Blastoma Therapy

September 11, 2017Immunotherapy ResearchAutoimmune Disease, Blastoma Therapy, CAR-Tbiolabs

Car-T for Autoimmune Disease An autoimmune disease is a pathological condition resulting from an abnormal immune response to tissues that can exist in the body, affecting up to 50 million Americans in termsRead More…

Posts navigation

  • « Previous
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 17
  • Next »

Categories

  • Antibody Engineering Research
  • Biological Knowledge
  • Drug Discovery Research
  • Immunotherapy Research
  • News

Recent Posts

  • Scientists identify a special gene that produces key antibodies in large quantities
  • The molecular mechanism by which special antibodies protect the body against HIV infection
  • Multispecific antibodies enhance cancer immunotherapy
  • Scientists have cracked HIV’s new way of entering the host cell nucleus, which may lead to new therapeutic drugs
  • Antibody sequencing provides a new path for antibody therapy research

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Drug Discovery Research
  • Immunotherapy Research
  • Antibody Engineering Research